RoslinCT and Lykan Bioscience, two leading Contract Development and Manufacturing Organizations (CDMOs) in the Cell and Gene Therapy industry, have announced their integration to form a unified business that will operate under the RoslinCT brand.
This integration, facilitated by GHO Capital, a global investment firm, aims to establish a dominant player in the Advanced Cell and Gene Therapy CDMO market.
RoslinCT, tracing its roots back to the historic cloning of Dolly the Sheep at the Roslin Institute within the University of Edinburgh (UK) in 1997, was established in 2006 to translate this cutting-edge science and apply it to the development of human medicines.
It has a strong focus on science and innovation and is one of the first in the world to produce clinical-grade human pluripotent stem cells.
The company is supporting the development of cell therapies based on a broad range of cell types, with the most advanced program being the first CRISPR-edited stem cell-based therapy for a major disease currently pending marketing authorization.
The newly formed organization, led by Peter Coleman in the UK and Patrick Lucy in the US, will offer a comprehensive range of services, including process development, analytical testing, clinical and commercial cGMP manufacturing, and cGMP iPSC cell line development, gene editing, and differentiation.
These services will empower Cell and Gene Therapy developers to advance their products through clinical trials and bring them to market.
The state-of-the-art manufacturing facilities located in Edinburgh, Scotland, and Boston, USA, will remain operational under the RoslinCT brand, with plans for further capacity expansion on both sides of the Atlantic, to meet the global growing demand for Advanced Cell and Gene Therapy manufacturing services.